Bank Of America Corp Bei Gene, Ltd. Transaction History

Bank Of America Corp

$1.06 Trillion
Q1 2024

A detailed history of Bank Of America Corp transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Bank Of America Corp holds 353,102 shares of BGNE stock, worth $52.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

353,102

Previous 176,392 100.18%

Holding current value

$52.6 Million

Previous $31.8 Million 73.57%

% of portfolio

0.01%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$141.8 - $181.47 $25.1 Million - $32.1 Million	176,710 Added 100.18%	353,102 $55.2 Million
Q4 2023 Feb 14, 2024	SELL	$158.67 - $201.58 $18.2 Million - $23.1 Million	-114,544 Reduced 39.37%	176,392 $31.8 Million
Q2 2023 Aug 14, 2023	SELL	$178.3 - $266.78 $3.53 Million - $5.29 Million	-19,825 Reduced 6.38%	290,936 $51.9 Million
Q1 2023 May 12, 2023	SELL	$215.53 - $274.5 $699,610 - $891,027	-3,246 Reduced 1.03%	310,761 $67 Million
Q4 2022 Feb 10, 2023	BUY	$125.51 - $229.3 $1.57 Million - $2.87 Million	12,501 Added 4.15%	314,007 $69.1 Million

Q3 2022 Nov 14, 2022	SELL	$131.8 - $202.24 $6.17 Million - $9.46 Million	-46,785 Reduced 13.43%	301,506 $40.6 Million
Q2 2022 Aug 12, 2022	SELL	$121.11 - $216.05 $8.01 Million - $14.3 Million	-66,175 Reduced 15.97%	348,291 $56.4 Million
Q1 2022 May 16, 2022	BUY	$146.52 - $269.56 $26.4 Million - $48.6 Million	180,470 Added 77.13%	414,466 $78.2 Million
Q4 2021 Feb 08, 2022	SELL	$248.56 - $389.34 $13.9 Million - $21.8 Million	-55,971 Reduced 19.3%	233,996 $63.4 Million
Q3 2021 Nov 15, 2021	BUY	$249.6 - $403.14 $4.05 Million - $6.55 Million	16,237 Added 5.93%	289,967 $105 Million
Q2 2021 Sep 13, 2021	BUY	$292.75 - $367.01 $80.1 Million - $100 Million	273,730 New	273,730 $93.9 Million

Others Institutions Holding BGNE

# of Institutions

216

Shares Held

45.1M

Call Options Held

76.5K

Put Options Held

72.3K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $15.4B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Bei Gene, Ltd. Transaction History